Victoria Socha

DocwireNews

In previous clinical trials of patients with advanced renal cell carcinoma (aRCC), including CheckMate 214, patients with brain metastases have been excluded. However, according to Hamid Emamekhoo, MD<a href="https://www.med.wisc.edu/">,</a> and colleagues, antitumor activity has been observed in patients with melanoma treated with nivolumab (1 mg/kg) plus ipilimumab 3 mg/kg) with brain metastases; antitumor activity has also been observed in patients with non-small cell lung cancer treated with nivolumab (240 mg) plus ipilimumab (1 mg/kg).During a poster session at the ASCO 2019 Annual Meeting, the researchers presented safety and efficacy results of the CheckMate 920 trial, an ongoing, phase 3b/4 clinical trial of nivolumab plus ipilimumab in patients with aRCC not on corticosteroids or receiving radiation with Karnofsky performance status &ge;70%. The poster was titled Safety and Efficacy of Nivolumab plus Ipilimumab (NIVO+IPI) in Patients with Advanced Renal Cell Carcinoma (aRCC) with Brain Metastases: Interim analysis of CheckMate 920.Eligible patients were assigned to treatment with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks. Treatment continued until disease progression, unacceptable toxicity, or for a maximum of 2 years.The primary end point of interest was the incidence of high-grade immune-mediated adverse events. Secondary end points included progression-free survival and objective response rate by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per investigator. Additional safety analyses and overall survival were exploratory end points.A total of 28 patients were enrolled in the <a href="https://www.docwirenews.com/docwire-pick/nephrology-picks/sequential-treatment-for-patients-with-arcc/">brain metastases</a> cohort. During a minimum follow-up of 6.47 months, there were six cases of grade 3 to 4 immune-mediated adverse events within 100 days of the last dose. Grade 3 to 4 immune-mediated adverse events observed in &ge;1 patents were diarrhea, colitis, diabetic ketoacidosis, immune-mediated hepatitis, hypophysitis, and rash of any type (n=1 each). There were no treatment-related immune-mediated adverse events grade 5 reported.Median progression-free survival in all treated subjects was 9.0 months. Median overall survival has not been reached.&ldquo;In patients with aRCC and brain metastases who are often excluded from clinical trials, nivolumab plus ipilimumab treatment showed a safety profile consistent with previous reports of this dosing regimen, with encouraging antitumor activity,&rdquo; the researchers said.NCT02982954Source: Emamekhoo H, Olsen M, Carthon BC, et al. Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

CheckMate 920: Efficacy and Safety Interim Results

ASCO 2019

In previous clinical trials of patients with advanced renal cell carcinoma (aRCC), including CheckMate 214, patients with brain metastases have been excluded. However, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe